A PKA inhibitor
货号:ajcx25494
CAS:N/A
分子式:C53H100N20O12·XCF3COOH
分子量：1209.5
溶解度:DMSO: 1 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml
纯度：98%
存储：Store at -20°C
库存：现货

Background:

PKI (14-22) amide (myristoylated) is a cell-permeable peptide inhibitor of protein kinase A (PKA).^1,2,3It inhibits PKA activity in mouse brain or spinal cord lysates when used at a concentration of 75 µM.¹PKI (14-22) amide (myristoylated) reduces IgG-dependent phagocytosis of heat-killedS. cerevisiaeby isolated human neutrophils in a concentration-dependent manner.²It inhibits the replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in human umbilical vein endothelial cells (HUVECs; IC₅₀s = 17.75, 22.29, 34.09, and 19.19 µM, respectively).³PKI (14-22) amide (myristoylated) (2.5 nmol, i.c.v.) increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice.¹

1.Dalton, G.D., Smith, F.L., Smith, P.A., et al.Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI)Neuropharmacology48(5)648-657(2005) 2.Ydrenius, L., Majeed, M., Rasmusson, B.J., et al.Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosisJ. Leukoc. Biol.67(4)520-528(2000) 3.Cheng, F., da Silva, S.R., Huang, I.-C., et al.Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22J. Virol.92(4)e02019-02017(2018)